Home / Tag Archives: MENA (page 5)

Tag Archives: MENA

Feed Subscription

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Provident Bancorp, Inc. Investors to Inquire About Securities Class Action Investigation – PVBC

NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Provident Bancorp, Inc. (NASDAQ: PVBC) resulting from allegations that Provident may have issued materially misleading business information to the investing public. SO WHAT: If you purchased […]

Read More »

CORZ IMPORTANT DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Core Scientific, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important January 13 Deadline in Securities Class Action – CORZ

NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Core Scientific, Inc. (NASDAQ: CORZ) between January 3, 2022 and October 26, 2022, both dates inclusive (the “Class Period”), of the important January 13, 2023 lead plaintiff deadline. SO WHAT: If […]

Read More »

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Bird Global, Inc. Investors to Secure Counsel Before Important January 17 Deadline in First Filed Securities Class Action Commenced by the Firm – BRDS

NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Bird Global, Inc. (NYSE: BRDS) between May 14, 2021 and November 14, 2022, both dates inclusive (the “Class Period”), of the important January 17, 2023 lead plaintiff deadline in the securities class […]

Read More »

Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)

Global Phase 3 INDIGO study will evaluate the efficacy and safety of obexelimab in patients with IgG4-RD, a chronic and serious fibroinflammatory disease typically affecting multiple organs IgG4-RD is the first of several potential disease indications to be pursued for obexelimab given its unique non-depleting, B-cell inhibition WALTHAM, Mass., Jan. 11, 2023 (GLOBE NEWSWIRE) — […]

Read More »

Nikkiso Clean Energy & Industrial Gases Group Announces their First On-Site FAT Testing at their Marine Facility in Busan, Korea

TEMECULA, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) — Nikkiso Clean Energy & Industrial Gases Group (“Group”), a part of the Nikkiso Co., Ltd (Japan) group of companies, is proud to announce its first on-site FAT testing at their new Marine facility in Busan, Korea. This accomplishment exemplifies their commitment to and support of the growth […]

Read More »
Scroll To Top